Hexarelin: The Strongest GHRP Protocol

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/hexarelin-protocol

Disclaimer: This content is for educational purposes only and is not medical advice. Hexarelin is a research compound, is not FDA-approved for human use, and is banned by WADA for in-competition and out-of-competition use. Consult a licensed healthcare provider before considering any peptide protocol.

Overview

Maximum GH release with cardioprotective benefits. Dosing protocols, desensitization prevention through cycling, stacking strategies, and how Hexarelin compares to other growth hormone-releasing peptides (GHRPs).

Hexarelin (also called Examorelin) is a synthetic hexapeptide developed from the GHRP-6 lineage by the research groups associated with Deghenghi and Locatelli in the early 1990s. A methyl modification on one of its tryptophan residues makes it the most potent GH releaser per microgram in the GHRP family. What truly distinguishes Hexarelin, however, is its dual mechanism — it activates the standard ghrelin receptor (GHSR-1a) like other GHRPs, but it also binds the CD36 scavenger receptor in cardiac tissue, generating preclinical interest as a cardioprotective agent.

Key Properties:

• 6 amino acid sequence (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2)
• Most potent GHRP by molar dose
• Dual receptor activity: GHSR-1a + CD36
• Pronounced acute GH pulse
• Significant desensitization risk with continuous dosing
• Not FDA-approved; research-use only

Mechanism of Action

Hexarelin operates through two complementary pathways that together produce its unique pharmacological profile:

1. GHSR-1a agonism (powerful) — Hexarelin binds the growth hormone secretagogue receptor in the pituitary and hypothalamus, mimicking ghrelin. Per microgram, it produces a larger GH pulse than GHRP-6, GHRP-2, or Ipamorelin in head-to-head animal data.
2. CD36 receptor activity (cardiac) — Hexarelin binds the CD36 scavenger receptor on cardiomyocytes. Preclinical work suggests this is GH-independent and may underlie its cardioprotective effects.
3. Somatostatin suppression — Like other GHRPs, Hexarelin reduces the inhibitory tone that normally caps GH pulses.
4. Synergy with GHRH — Co-administration with a GHRH analog (CJC-1295, Sermorelin) produces a multiplicative — not additive — GH response.
5. Downstream IGF-1 elevation — The acute GH pulse drives a delayed rise in hepatic IGF-1 production.

The catch: that same potency drives the fastest desensitization curve of any GHRP at clinically used doses.

Cardioprotective Properties

This is what sets Hexarelin apart from every other GHRP. Animal studies — primarily in rodent models of myocardial infarction and ischemia-reperfusion injury — suggest Hexarelin may:

• Preserve left ventricular function after experimental infarction
• Reduce cardiomyocyte apoptosis in ischemic tissue
• Attenuate post-MI cardiac remodeling
• Improve cardiac output in GH-deficient cardiomyopathy models

These effects appear to be mediated, at least in part, by CD36 binding rather than by GH release itself, because they are observed in hypophysectomized animals (no functional pituitary) and at doses below those needed for substantial GH release.

Important hedge: Human cardiology trials are extremely limited. A handful of small clinical studies in the late 1990s and 2000s explored cardiac effects in patients with GH deficiency and dilated cardiomyopathy, but Hexarelin has not been advanced as a cardiology drug, and current evidence does not support its clinical use for heart disease.

Dosing Protocols

Hexarelin is dosed more conservatively than other GHRPs because of its potency and desensitization profile. Most protocols target a single saturating dose rather than escalating.

Timing & Administration

• Route: Subcutaneous injection (insulin syringe, 29-31 gauge)
• Fasting window: 2 hours fasted before, 30-60 min after — carbs/insulin blunt the GH pulse
• Best timing: Pre-bed (preserves nocturnal pulse) and/or fasted morning

Desensitization — The Key Issue

Read this section carefully. It is the single most important factor in designing a Hexarelin protocol.

Hexarelin causes more pronounced pituitary desensitization than any other commonly used GHRP. Continuous daily dosing produces:

• A blunted GH response within 7-14 days
• A near-complete loss of acute GH pulse by 3-4 weeks at moderate-to-high doses
• Possible attenuation of endogenous GH pulsatility during the dosing window

Mechanistically, this reflects GHSR-1a downregulation, somatotroph exhaustion, and possible somatostatin tone reset. Recovery after cessation is generally complete, but it takes weeks — which is why cycling is non-negotiable with Hexarelin, not optional.

This is why dosing protocols cap out around 200 mcg per shot and why cycles run shorter than with Ipamorelin or CJC-1295.

Hexarelin vs Other GHRPs

The pattern is clear: Hexarelin trades cleanness and sustainability for raw potency and a unique cardiac mechanism.

Expected Outcomes

Acute (single dose):

• GH spike within 15-30 minutes, peaking around 60 min
• Subjective: mild flush, occasional hunger, transient fatigue
• IGF-1 not meaningfully changed from one dose

Week 1-2 (cycled):

• Strongest GH pulses
• Improved recovery from training
• Possible sleep deepening (when dosed pre-bed)
• IGF-1 begins to rise

Week 3-4:

• Plateau begins — GH response diminishes
• This is the natural ceiling of a Hexarelin cycle
• Time to taper or stop

Beyond 4 weeks (daily, no cycling):

• Diminishing returns
• Possible blunting of endogenous pulsatility
• Cortisol/prolactin creep at higher doses
• Not recommended

Side Effects & Safety

Hexarelin has the least clean side-effect profile of the modern GHRPs.

Common:

• Cortisol elevation — Significant at doses >150 mcg, especially with multiple daily injections
• Prolactin elevation — Highest of the GHRPs alongside GHRP-2
• Water retention — Mild to moderate, especially early in a cycle
• Hunger spike — Pronounced post-injection, similar to GHRP-6
• Injection site reactions — Mild redness, usually self-limiting
• Transient flushing or tingling

Less Common:

• Headache, lethargy, irritability
• Numbness/tingling in extremities (typically GH-mediated, transient)
• Mild glucose tolerance changes

Theoretical / Speculative:

• Chronic CD36 binding has unknown long-term effects in healthy human cardiac tissue. CD36 is involved in cardiac fatty acid uptake and inflammatory signaling — this is why short cycles matter beyond just desensitization.

Contraindications:

• Active malignancy
• Pregnancy / breastfeeding
• Uncontrolled hypertension or recent cardiac event
• Use of other GHSR agonists concurrently
• Competitive athletes subject to WADA (banned substance)

Stacking

Hexarelin + CJC-1295 (no DAC) or Sermorelin

The most justified Hexarelin stack. GHRH analogs preserve pulsatility while Hexarelin provides the GHRP signal. Synergy is preserved across short cycles.

• Hexarelin: 100 mcg, 1-2x daily
• CJC-1295 (no DAC): 100 mcg, same injection
• Cycle: 2-3 weeks on, 4 weeks off

Hexarelin + BPC-157

For injury-recovery phases. BPC-157 provides tissue-level repair while a short Hexarelin pulse supports GH-mediated systemic recovery.

• Hexarelin: 100 mcg pre-bed
• BPC-157: 250-500 mcg/day
• Cycle: align with Hexarelin's 2-3 week window

Do NOT Stack

• With other GHRPs (Ipamorelin, GHRP-2, GHRP-6, MK-677) — receptor competition, redundant desensitization, no upside
• With high-dose corticosteroids — additive cortisol axis disruption
• With long-acting CJC-1295 (with DAC) during a Hexarelin pulse — defeats the pulsatile rationale

Cycling — Critical

Cycling is not a recommendation with Hexarelin. It is the protocol.

Pulse Cycle (Most Common)

• On: 2-3 weeks at 100-150 mcg, 1-2x daily
• Off: 4 weeks minimum washout
• Repeat: Up to 3-4 pulse cycles per year
• Rationale: Captures peak responsiveness window before desensitization sets in

Maximum Single Cycle

• 4 weeks at moderate dose. Beyond this, GH response is typically negligible and side-effect burden rises.

Low-Dose Maintenance (Less Common)

• 50-100 mcg once daily pre-bed for 12-16 weeks
• Used by some researchers exploring the cardiac/CD36 angle rather than GH output
• Still requires a 4-8 week washout after

Always Pair Cycling With:

• Bloodwork before and after (IGF-1, fasting glucose, prolactin, morning cortisol)
• A clear washout — no "bridging" with another GHRP
• Honest tracking: if subjective effects vanish at week 2, stop early

Frequently Asked Questions

Q: Why are Hexarelin cycles so short compared to Ipamorelin? A: Hexarelin desensitizes the GHSR-1a receptor and the somatotroph response much faster than Ipamorelin. By week 3-4 of daily dosing, most users see a near-flat GH response. Short cycles preserve the very mechanism you're paying for.

Q: Hexarelin vs GHRP-2 — which is better? A: Depends on the goal. GHRP-2 is potent and cheaper but raises prolactin and cortisol notably. Hexarelin is more potent per mcg, has the unique CD36 mechanism, but desensitizes faster. For a sustainable daily protocol, neither is ideal — Ipamorelin wins. For a short, hard GH pulse with cardiac research interest, Hexarelin.

Q: Is the cardioprotective benefit real in humans? A: Preclinical evidence is genuinely interesting. Human clinical evidence is limited to small studies from the late 1990s and 2000s. Hexarelin is not an approved cardiology drug, and current data do not support using it to treat heart disease. The mechanism is intriguing; the clinical case is unproven.

Q: Is desensitization permanent? A: No, current evidence suggests it is fully reversible with adequate washout (typically 4+ weeks). However, repeated long cycles without proper recovery may extend the recovery window.

Q: Can I stack Hexarelin with Sermorelin? A: Yes, this is one of the more rational Hexarelin stacks. Sermorelin (or CJC-1295 no-DAC) provides the GHRH signal; Hexarelin provides the GHRP signal. They are synergistic, not redundant. Keep the cycle short regardless.

Q: Does Hexarelin raise cortisol enough to matter? A: At 100 mcg per shot, cortisol elevation is typically modest. At 200 mcg, especially 2-3x daily, it becomes clinically relevant — comparable to GHRP-2. Bloodwork (morning cortisol, prolactin) before and after a cycle is the right move.

Q: Can I use Hexarelin as a pre-workout? A: Some users do, 30-45 minutes before training. The acute GH pulse is real but the practical performance benefit is debatable. The bigger payoff is post-training recovery via the IGF-1 lift over the cycle.

Q: What bloodwork should I run? A: Baseline and end-of-cycle: IGF-1, fasting glucose, HbA1c, prolactin, morning cortisol, and a basic metabolic panel. If using long-cycle low-dose for cardiac reasons, add lipids and hs-CRP.

Related Content

• Ipamorelin Protocol
• CJC-1295 Protocol
• Growth Hormone Peptide Stacking Guide
• Bloodwork Checklist
• Reconstitution Cheat Sheet

Disclaimer: This content is for educational purposes only and is not medical advice. Hexarelin is a research compound, is not FDA-approved for human use, and is on the WADA Prohibited List. Cardioprotective claims are based on preclinical research and limited early-phase human studies; they should not be interpreted as clinical recommendations. Consult a licensed healthcare provider before starting any peptide protocol.

Source: https://peptides.nyc/learn/hexarelin-protocol